Table 4 ILD-related hospitalization rate per 1000 PY, unadjusted
Cohort | Specific definition | Sensitive definition |
|---|---|---|
Events (total PY) | Events (total PY) | |
Rate (95 % CI) | Rate (95 % CI) | |
All eligible | 4 (61) | 42 (329) |
65.8 (17.9–68.4) | 127.7 (92.0–172.6) | |
Anti-TNFα agents | 1 (28) | 17 (152) |
35.2 (0.9–195.9) | 111.9 (65.2–179.1) | |
Etanercept | 1 | 6 (33) |
261.5 (6.6–1456.7) | 180.6 (66.3–393.1) | |
Adalimumab | 0 | 3 (45) |
0.0 (0.0–253.9) | 67.4 (13.9–197.0) | |
Infliximab | 0 | 4 (15) |
0.0 (0.0–1445.4) | 262.5 (71.5–672.2) | |
Certolizumab | 0 | 2 (28) |
0.0 (0.0–761.4) | 72.2 (8.7–260.7) | |
Golimumab | 0 | 2 (31) |
0.0 (0.0–439.8) | 63.9 (7.7–230.8) | |
Tocilizumab | 1 | 2 (36) |
128.7 (3.3–717.1) | 55.6 (6.7–200.7) | |
Rituximab | 1 (13) | 16 (68) |
78.8 (95 % CI 2.0–439.1) | 234.2 (95 % CI 133.8–380.3) | |
Abatacept | 1 | 7 (73) |
83.8 (95 % CI 2.1–467.0) | 96.5 (95 % CI 38.8–198.7) |